SELIKA GUTIERREZ-BORST, MS, RN
845 N. Michigan Ave #923E
Chicago, IL 60611
Selikab15@yahoo.com
Selika@DrDayan.com

LICENSURE Illinois Registered Professional Nurse 041-306701

EDUCATION

2004- 2007 North Park University
Chicago, IL
MS, Master of Science Degree- May, 2007
APN, Adult Nurse Practitioner Degree- May, 2007

2003 - 2004 Loyola Niehoff School of Nursing
Chicago, IL
Adult Nurse Practitioner
Clinical Nurse Specialist

2001-2002 Benedictine University
Lisle, IL
BSN, Bachelor of Science in Nursing, December, 2002

1993-1995 Olive-Harvey College
Chicago, IL
ADN, Associates Degree in Nursing - December, 1995
Associates of Applied Sciences Degree - December, 1995

1990-1992 The University of Illinois
Champaign-Urbana, IL
Undergraduate prerequisites in Liberal Arts

ANP TRAINING

January 2006- May 2007 Internal Medicine nurse practitioner rotation
(including women's and adolescent health)
West Loop University Medicine
(David Buyer, MD and Jodi Bult, ANP)
Chicago, IL

March 2007- May 2007 Community Mental Health nurse practitioner rotation
Thresholds Community Mental Health Center
(Jagannath Devulapally, M.D.)

Chicago, IL

October- November 2006 — Orthopedic surgery nurse practitioner rotation
Midwest Orthopedics (Aaron Rosenberg, MD)
Chicago, IL

September -October 2006 — Cardiology nurse practitioner rotation
Associates in Cardiology (Neal Ruggie, MD)
Chicago, IL

EXPERIENCE

September 2017- present — Clinical Director of Aesthetics Division
Arano, LLC dba DeNova Research
Dr. Steven Dayan
845 North Michigan Ave suite 923 East
Chicago, IL 60611

October 2013-present — Clinical Practice Manager
Chicago Center for Facial Plastic
845 N. Michigan Ave suite 923East
Chicago, IL 60611

March 2012- present — Pre-op/Post-op Nurse
Chicago Center for Facial Plastic
845 N. Michigan Ave suite 923East
Chicago, IL 60611

October 2010- present — Clinical Director of Aesthetics Division
DeNova Research
Dr. Steven Dayan
845 North Michigan Ave suite 923 East
Chicago, IL 60611

September 2008- present — Adjunct Instructor
True University
Research clinical instructor
Chicago, IL 60611

August 2008- present — Private Practice Clinical Nurse Injector
Chicago Center for Facial Plastic

Steven Dayan, MD
845 North Michigan Avenue suite 923 East
Chicago, IL 60611

June 2008- present — Intern Preceptor
DeNova Research
Steven Dayan, MD
845 North Michigan Ave suite 923 East
Chicago, IL 60611

June 2008- Oct 2010 — Assistant Director of Clinical Research
DeNova Research
Dr. Steven Dayan
845 North Michigan Ave suite 923 East
Chicago, IL 60611

May 2007- 2014 — Home Health On-Call RN
Health Resource Solutions (HRS)
Chicago, IL

August 2007- June 2008 — Adjunct faculty
Elmhurst College
Psychiatric Mental Health clinical instructor
Elmhurst, IL

September 2006- 2007 — Consultant
Community Mental Health Council-
Child/Adolescent Schizophrenia Evaluator
Chicago, IL

July 2006-2007 — Consultant
Honorary Nurse Practitioner Advisory Board
Glaxo-Smith Klein

March 2006- 2008 — Consultant
Astra Zeneca Pharmaceuticals- Speaker

May 2004--2008 — Consultant
Janssen Pharmaceuticals- Speaker

September 2003-2008	Consultant Bristol-Myers Squibb Speaker July 2006
July 2003-June 2008	Program Coordinator Rush University Medical Center Treatment Research Center 1700 W. Van Buren St., 5th Floor Chicago, IL 60612
June 2001-June 2008	Study Coordinator Psychiatric Medicine Associates, LLC 9669 Kenton Ave., Suite 209 Skokie, IL
June 2001-2003	Program Coordinator Rush-Presbyterian-St. Luke's Medical Center Treatment Research Center 1725 W. Harrison St., Suite 955 Chicago, IL
June 2001-June 2008	Private Practice Nurse John Zajecka, MD Psychiatric Medicine Associates, LLC 9669 Kenton Ave., Suite 209 Skokie, IL
May 2001-2008	Consultant Eli Lilly – Neuro Treatment Team Partners – Speaker Indianapolis, IN
May 2000-2003	Clinical Research Coordinator Treatment Research Center Rush North Shore Medical Center 9669 Kenton Ave., Suite 209 Skokie, IL
May 2000-May 2001	Clinical Research Coordinator

Rush-Presbyterian-St. Luke's Medical Center
Rush Institute for Mental Well-Being
1725 W. Harrison St., Suite 955
Chicago, IL

August1996-May2000 Registered Nurse
Float Pool Nurse (med/surg/orthopedics)
Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL

August 1996-May 2000 Registered Nurse
Inpatient acute adult, child/adolescent psychiatric nurse
Registered nurse preceptor
Assistant group coordinator
Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL

May 1993 - August 1996 Student Nursing Assistant I, II
Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL

PEER-REVIEWED PUBLICATIONS:

Dayan SH, Bacos JT, Ho TT, Gandhi ND, Gutierrez-Borst S, Kalbag A. Topical. skin therapies in subjects undergoing full facial rejuvenation. J Cosmet. Dermatol. 2019 Apr 29. doi: 10.1111/jocd.12977

Dayan SH, Thuy-Van TH, Bacos JT, Gandhi ND, Kalbag A, Gutierrez-Borst S. A Randomized Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination with Nuerotoxin and Full Facail Filler Treatments. J Drugs Dermatol. 2018 Jan 1;17(611-617)

Dayan SH, Bacos J, Ho Thuy-Van, Gandhi N, Gutierrez-Borst S. A Pilot Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant in External Rhinoplasty. Aesth Plast Surg. 2017 Nov

Dayan SH, Cho K, Siracusa M, Gutierrez-Borst S. Quantifying the Impact Cosmetic Make-up Has on Age Perception and the First Impression Projected. JDrugs Dermatol. 2015 April 1;14(4):366-374.

Dayan SH, Arkins JP, Antonucci C, Borst S. Influence of the chin implant on cervicomental angle. Plast Reconstr Surg. 2010 Sep;126(3):141e-3e.

Zajecka J, Gutierrez S. Oral Divalproex Sodium Loading for Adolescent Outpatients With Acute Mania/Hypomania. (published -Journal of Clinical Psychiatry, June, 2008)

Zajecka JM, Gutierrez S, Mackey I, Goldstein C, Miles WM, Shulman RS, Devulapally J. Augmentation with aripiprazole to partial responders on SSRIs or SNRIs for depression. (submitted for publication)

Zajecka JM, Gutierrez S, Mackey I, Goldstein C, Miles WM, Shulman RS, Devulapally J. A Double-Blind Comparison of the Efficacy and Safety of Nefazodone vs. Venlafaxine in Outpatients with Generalized Anxiety Disorder. (submitted for publication)

SCIENTIFIC ABSTRACTS/POSTERS:

Selika Gutierrez-Borst, MS, RN;[1] Steven H. Dayan, MD;[1] Shannon Humphrey, MD;[2] Christine Somogyi[3] Efficacy and Safety of ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Pooled Analysis of the Phase 3 REFINE Data. NADNP annual meeting; May 9-14, 2016 Clearwater Beach, Flordia.

Zajecka J, Gutierrez S, Mackey I. Augmentation with aripiprazole to partial responders on SSRIs or SNRIs for depression (poster). Accepted for presentation at the 45th Annual New Clinical Drug Evaluation Unit meeting; June 6-9, 2005 Boca Raton, Florida.

S Gutierrez, Zajecka J. Oral divalproex sodium loading for adolescents in acute mania (poster). Accepted for presentation at US Psychiatric and Mental Health Congress Annual Meeting; November 18021, 2004 San Diego, California.

RESEARCH:

Jan 2020 Clinical Director of Research
A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis
Sponsor: Vanda Pharmaceuticals Inc.
Protocol: VP-VLY-686-3102

Jan 2020 Clinical Director of Research
A Single Blind, Randomized, Placebo-controlled, Phase 2, 2-cohort Study for the Evaluation of Efficacy and Safety of RZL-012 for Submental Fat Reduction in Healthy Volunteers
Sponsor: Raziel Therapeutics
Protocol: RZL-012-SMF-P2aUS-001

Jan 2020 Clinical Director of Research
A histological study evaluating silk voice and crosslinked hyaluronic acid filler
Sponsor: Sofregen Medical Inc.
Protocol: SOF-003

Jan 2020 Clinical Director of Research
Effects of *Restylane-L*® Filler Injection for Non-Surgical Rhinoplasty on First Impressions and Quality of Life (FACE-Q Scale)
Sponsor: Steven Dayan, MD
Protocol: RRFI-2019

Dec 2019 Clinical Director of Research
Safety and Efficacy of the Onix Microneedling Fractional Radiofrequency System for Neck and Jaw Lifting and Tightening: A Pilot Study
Sponsor: Aesthetics Biomedical Inc.
Protocol: 2019-004

Nov 2019 Clinical Director of Research
A real world, multicenter, open-label, multiple dose study to assess the effectiveness of, and satisfaction with, CCH treatment of buttock or thigh cellulite in adult females
Sponsor: Endo Pharmaceuticals Inc.
Protocol: EN3835-305

Nov 2019 Clinical Director of Research
A randomized, controlled, double-blinded, within-subject (split-face), multicenter, prospective clinical study to compare the level of pain using the dermal filler RHA® 1 formulated with two different anesthetics in the treatment of perioral rhytids
Sponsor: Teoxane SA
Protocol: TEO-RHA-1801

Nov 2019 Clinical Director of Research

A randomized, controlled, double-blinded, within-subject (split-face), multicenter, prospective clinical study to compare the level of pain using the dermal filler RHA® 4 formulated with two different anesthetics in the treatment of nasolabial folds
Sponsor: Teoxane SA
Protocol: TEO-RHA-1802

Sept 2019 Clinical Director of Research
Effects of *Restylane® Lyft* Filler Injection for Hand Rejuvenation on First Impressions
Sponsor: Steven Dayan, MD
Protocol: REST-HAN-2019

Sept 2019 Clinical Director of Research
The INFORM Study: A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring with an Optimized Post-Procedure Treatment Plan
Sponsor: Recros Medica
Protocol: CLP-0006

April 2019 Clinical Director of Research
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double-Blind, Multi-Dose, Placebo Controlled Study
Sponsor: Allergan
Protocol: 1789-202-008

May, 2019 Clinical Director of Research
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Protocol: 1936-201-008

May, 2019 Clinical Director of Research
The Use of Radio Frequency in Premature Jowl and Neck Laxity Following Facialplasty
Protocol: DO608522A

February, 2019 Clinical Director of Research
Development of CliniRo and PRO Instruments for Facial Lines
Protocol: GAL1746

February, 2019 Clinical Director of Research
A Multicenter, Randomized, Dose-Ranging, Double-Blind Placebo-Controlled Study to Evaluate
the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe
Glabellar Lines
Protocol: 43USD180

February, 2019 Clinical Director of Research
A Multi-Center, Open-Label, Long-Term Safety
Study of S5G4T-1 to Evaluate the Safety of S5G4T-1
in Papulopustular Rosacea Patients
Protocol: SGT-54-07

January, 2019 Sub-Investigator
A Phase 3 Multi-Center, Double-Blind,
Randomized, Vehicle-Controlled Study of
S6G5T-3 in the Treatment of Acne Vulgaris
Protocol: SGT-65-04

January, 2019 Clinical Director of Research
A Phase 3 Multi-Center, Double-Blind,
Randomized, Vehicle-Controlled Study of
S6G5T-3 in the Treatment of Acne Vulgaris
Protocol: SGT-65-04

October, 2018 Sub-Investigator
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition
Protocol: V25L-002

October, 2018 Clinical Director of Research
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition
Protocol: V25L-002

September, 2018 Clinical Director of Research
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Protocol: SGT-54-02

March, 2018 Clinical Director of Research
A Multi-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring
Protocol: CLP-002

January, 2018 Clinical Director of Research
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of an Oral Nutraceutical Supplement with Standardized Botanicals in Males with Self-Perceived Thinning Hair and Loss
Protocol: HAIR-2018

November, 2017 Clinical Director of Research
Premaxillary injection for the perioral rejuvenation and upper lip enhancement
Protocol: REST-DEF-2017

August, 2017 Clinical Director of Research
A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects with Mild to Moderate Atopic Dermatitis.
Protocol: ADB244-001

April, 2017 Clinical Director of Research
Open label prospective study evaluating the effectiveness and quality of life impact after one thermistor controlled subsurface radiofrequency neck treatment on patients with post face lift laxity
Protocol: THERMI-01-16

February, 2017 Clinical Director of Research
An Open-label multi-center trial to assess the safety of single and repeat treatments of DaxibotulinumtoxinA for Injection for treatment of moderate to severe glabellar lines
Protocol: 1620303

October, 2016 Clinical Director of Research
Multicenter, Randomized, double-blind, placebo-controlled, phase 2A study of setipirant tablets, with an independent evaluator masked comparator, in androgenetic alopecia in males
Protocol: 1922-201-002

October, 2016 Clinical Director of Research
A multicenter, single-blind, randomized, controlled study of the safety and effectiveness of Juverderm Voluma XC injectable gel for chin augmentation

Sponsor: Allergan
Protocol: VOLUMA-006

April, 2016 Clinical Director of Research
Randomized double-blind Phase3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study
Sponsor: CROMA
Protocol: CPH-301-201030/Blessed I

February, 2016 Clinical Director of Research
A Post-Market, Randomized, Placebo-Controlled Study to Assess the Efficacy of Cosmeceutical therapy in Combination with Full Facial Rejuvenation
Sponsor: DeNova Research/PCA Skin
Protocol: PCA-SD-01

October, 2015 Clinical Director of Research
An Open-label, post-market study to assess the impact of lip rejuvenation with Restylane Silk on projected first impressions and mood perceptions
Sponsor: DeNova Research/ Galderma
Protocol: Silk-FL-01

October, 2015 Clinical Director of Research
A post market, randomized study to assess the efficacy of skin rejuvenation therapy in combination with neurotoxin and full facial filler treatments
Sponsor: DeNova Research/ Valeant Pharmaceuticals
Protocol: NuD-SD-01

June, 2015 Clinical Director of Research
Clinical evaluation of the efficacy of the Dermaflash system for skin exfoliation and reduction of the face vellus hair
Sponsor: DDKarma
Protocol: DERM-15-001

May, 2015 Clinical Director of Research
A Multi-Center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-Severe Glabellar Lines
Sponsor: Evolus, Inc.
Protocol: EVOLUS - CLIN006

May, 2015 Clinical Director of Research
CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)
Sponsor: Kythera Biopharmaceuticals, Inc.
Protocol: ATX-101-15-40M

April, 2015 Clinical Director of Research
A MultiCenter, Randomized, DoubleBlinded, PlaceboControlled Study Evaluating the Safety and Efficacy of LIPO202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects
Sponsor: Neothetics
Protocol: LIPO-202-CL-19

April, 2015 Sub-Investigator
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Sponsor: Actavis
Protocol:SC1403

April, 2015 Clinical Director of Research
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Sponsor: Actavis
Protocol:SC1403

October, 2014 Sub-Investigator
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Sponsor: Actavis
Protocol: SC1401

October, 2014 Clinical Director of Research
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Sponsor: Actavis
Protocol: SC1401

May, 2014 Clinical Director of Research
Prospective, Multi-site, Single-blind Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychological Impact of Combined Facial Treatment of BOTOX® Cosmetic, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE®
Sponsor: Allergan
Protocol: GMA-CMA-14-001

March, 2014 Clinical Director of Research
A Post Market, Double-arm Study to Assess the Tolerance of Cosmeceutical Sunscreen in Adjunct to either abobotulinumtoxinA for Peri-Ocular Rhytides or Hyaluronic Acid Soft Tissue Filler in the Vermillion Body and/or Border.
Sponsor: SkinCeuticals
Protocol: SKI-SNSCRN-1

March, 2014 Clinical Director of Research
A Mulit-center, Double-blinded, Nontreatment, Long-term Follow-up Study of Subjects who Completed AXT-101 (Deoxycholic Acid Injections) Clinical Trials ATX0101-11-22 or AXT-101-11-23 for the reduction of Localized Subcutaneous Fat in the Submental Area
Sponsor: Kythera
Protocol: ATX-101-13-35

March, 2014 Clinical Director of Research
A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
Sponosr: Allergan
Protocol: 225678-007

October, 2013 Clinical Director of Research
A Prospective, multicenter, within-subject controlled study of the safety and effectiveness of Juverderm Volift XC verses Restylane-L for the correction of moderate to severe nasolabial folds
Sponsor: Allergan
Protocol: S17L-001

October, 2013 Clinical Director of Research
A Post Market, Triple-arm, Randomized, Controlled Study to
Assess the Efficacy of Cosmeceutical Therapy in Adjunct to Full Facial Rejuvenation
Sponsor: Dr. Dayan

Protocol: SKI-FIL-12

July, 2013 Clinical Director of Research
Dose Finding Study of BoNT/A In Subjects With Crow's Feet (Lateral Canthal Lines)
Sponsor:Anterios
Protocol: ANT-1401-LCL-204

June, 2013 Clinical Director of Research
Evaluation of Psychological Impact using the facial lines outcome-11 (FLO-11) questionnaire in forehead lines, glabellar lines, and crow's feet lines
Sponsor: Allergan

June, 2013 Clinical Director of Research
Content Validation of the facial wrinkle scale in subjects with forehead lines
Sponsor: Allergan

June, 2013 Clinical Director of Research
A Double-blinded, Randomized Placebo Controlled Study to Assess the Efficacy of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated with Aesthetic Procedures
Protocol: PS-SUP-12
Sponsor: Standard Process

January, 2013 Clinical Director of Research
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Protocol: 192024-043
Sponsor: Allergan

January, 2013 Clinical Director of Research
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evalute the Efficacy of the New Viviscal Professional Strength Oral Supplement in Females with Self-Perceived Thinning Hair
Protocol: VIV-HAI-12
Sponsor: Lifes to Good

December, 2012
Clinical Director of Research
Bimatoprost in the Treatement of Eyelash Hypotrichosis
Protocol: 192024-046
Sponsor: Allergan

September, 2012

Clinical Director of Research

Video recording to document the experience of subjects treated with ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental area

Protocol: ATX-101-12-34

Sponsor: Kythera

September, 2012

Clinical Director of Research

Prospective, Multi-center, Pivotal Trial Evaluating te Safety and Effectiveness of the Ulthera System for Improvement in Line and Wrinkles of the Decolletage

Protocol: ULT-129

Sponsor: Ulthera

September, 2012

Clinical Director of Research

Evaluation of the Ulthera System for Obtaining Lift and Tightening of the Neck in Post-surgery and Surgery Naïve Patients who failed to respond to a Previous Ultherapy Treatment

Protocol: ULT-127

Sponsor: Ulthera

July, 2012 Clinical Director of Research

Multi-center, randomized, double-blind, placebo-controlled, Phase 3 study of ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental area

Protocol: ATX-101-11-23

Sponsor: Kythera

August, 2012 Clinical Director of Research

A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as used in External Rhinoplasty

Protocol: ART-RHI-12

Sponsor: Baxter International

August, 2012 Clinical Director of Research
A Double- Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of Incobotuminumtoxin A versus Saline Injections to the Cheek Region in Patients with Rosacea
Protocol: ROS-INC-12
Sponsor: Merz Pharmaceuticals Inc

May, 2012 Clinical Director of Research
A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline, Compared to Placebo in the Treatment of Facial Acne Vulgaris
Protocol: PR-10411
Sponsor: Warner Chillcott

August, 2011 Clinical Director of Research
Multicenter, open-label study of ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental area
Protocol: ATX-101-11-26
Sponsor: Kythera

August, 2011 Clinical Director of Research
A double-blinded, placebo controlled, exploratory study to assess the sefl esteem in subjects treated with ATX (sodium deoxycholate injection) verses placebo for the reduction of localized subcutaneous fat in the submental area
Protocol: ATX-101-12-33
Sponsor: Kythera

August, 2011 Clinical Director of Research
Three-dimensional photography to document the time course of adverse events in the submental area for subjects treated with ATX-101 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental area
Protocol: ATX-101-11-31
Sponsor: Kythera

July, 2011 Clinical Director of Aesthetic Division, "A Pilot Study of Botox Cosmetic in the Treatment of Moderate to Severe Glabellar Lines-Establishing Patient Satisfaction"
Protocol: GMA-BTX-11-001
Sponsor: Allergan, Inc

October, 2010

Clinical Director of Aesthetic Division ,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Single Treatment Cycle Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Lateral Canthal Rhytides"
Protocol: 191622-098
Sponsor: Allergan, Inc.

October, 2010

Clinical Director of Aesthetic Division, "An Open-Label, Randomized, 2-Arm Parallel Study Comparing the Efficacy, Ease of Use, and Safety of PDS Plated Cartilagenous Grafting versus Non-Plated Cartilagenous Grafting as Performed through Endonasal Rhinoplasty"
Protocol: PDS-END-001
Sponsor: Physician Initiated

October, 2010

Clinical Director of Aesthetic Division, "A Split-faced Study Comparing the Efficacy of Biopelle Control Tactics in Subjects Undergoing Fractional CO_2 Laser Resurfacing"
Protocol: BIO-CON-10
Sponsor: Biopelle, Inc.

September, 2010

Clinical Director of Aesthetic Division,
"A Multicenter, Single-Blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel for Lip Augmentation"
Protocol: JULIDO-002
Sponsor: Allergan, Inc.

June, 2010

Assistant Director of Clinical research, "An Open-label, Prospective, Postmarket Study to Assess Altering First Impressions and Self-esteem Following Radiesse® Injections"
Protocol: RAD-IMP-001
Sponsor: BioForm Medical

May, 2010

Assistant Director of Clinical research,"A Prospective, Open-Label, 2-Arm Parallel Study Comparing the Safety and Efficacy of Ulthera® Ultrasound Therapy in the Tightening of Neck Skin in Patients with a History of Submentoplasty and/or Rhytidectomy vs. Patients Naïve to Submentoplasty or

Rhytidectomy"
Protocol: ULT-SUB-001
Sponsor: Ulthera Inc.

May, 2010

Assistant Director of Clinical research, "Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus: A multicentre, randomised, double-blind, placebo-controlled phase IV trial to evaluate the effect of Saxagliptin on the incidence of cardiovascular death, myocardial infarction or ischaemic stroke in patients with type 2 diabetes"
Protocol # BMS-477118
Sponsor: AstraZeneca LP

May, 2010

Assistant Director of Clinical research, "Postmarket study for the treatment of face, mandibular and submandibular areas using the SmartLipo Triplex"
Sponsor: Cynosure, Inc.

May, 2010

Assistant Director of Clinical research, "Postmarket study for the treatment of nasolabial folds using the SmartLipo Triplex"
Sponsor: Cynosure, Inc.

May, 2010

Assistant Director of Clinical research, "A double-blind, randomized, placebo controlled, crossover study to assess the safety and efficacy of botulinum toxin A injections as a preventative measure for herpes labialis"
Protocol # HSV-BOT-01-09
Sponsor: Physician Initiated

February 2010

Assistant Director of Clinical research, A Prospective, Randomized, Open-Label, 2-Arm Parallel Study Comparing the Safety and Efficacy of Single Therapy versus Double Therapy using the Surgitron® Dual RF™ S5 with the Pellevé™ Wrinkle Treatment Handpiece and Pellevé™ Treatment Gel for the Treatment of Moderate Facial Wrinkles in Fitzpatrick Skin Types I – IV
Ellman International, Inc

February 2010

Assistant Director of Clinical research, An open-Label, Single-Center, Post Market Study to Assess the Effectiveness of Dermacyte Oxygen Concentrate Gel Applied Twice Daily to the Face to Support and Improve Healthy Skin in Subjects

with Mild to Moderate Facial Wrinkles, Fine Lines and Crow's Feet
Oxygen Biotherapeutics, Inc

January 2010

Assistant Director of Clinical research, A Prospective, Open-Label Study Evaluating the Efficacy and Safety of the Intraceuticals Clarity Infusion for the Treatment of Mild to Moderate Facial Acne in Subjects with Fitzpatrick Skin Types I-VI.
Intraceuticals, Pty

January 2010

Assistant Director of Clinical Research, " Post Market Study for the Treatment of Mandibular and Submandibular Areas Using the Smartlipo Multiplex"
Cynosure, Inc

October 2009

Assistant Director of Clinical Research, "A Randomized, Double-Blind, Placebo-Controlled study of the efficacy and safety of nebivolol added to antihypertensive treatment with lisinopril or losartan in patients with hypertension"
Forest Labortories

August 2009

Assistant Director of Clinical Research, "A double blinded, prospective, randomized, stratified, placebo-controlled, multi-center study of photodynamic therapy with VisonacTM cream in patients with moderate to severe acne vulgaris"
Photocure

May 2009

Assistant Director of Clinical Research, "Open label comparison study of Botox verses Placebo in a 3-month Quality of Life Survey"
Investigator Initiated

February 2009

Assistant Director of Clinical Research, "Open-label, Randomized syringe comparison study of Radiesse, Jevederm and Restylane in patients with Moderate Nasal Labial Folds"
Bioform

December 2008

Assistant Director of Clinical Research, "Botox 3-month Quality of Life Survey"
Investigator Initiated

November 2008

Assistant Director of Clinical Research, "An Open-label, Multicenter, Prospective, Postmarket Study to Assess the Safety and Effectiveness of Evolence in Facial Augmentation of Subjects with Fitzpatrick Skin Color types Iv, V and VI
Colbar LifeScience Ltd

September 2008

Assistant Director of Clinical Research, "A Randomized, Double-blind, Multicenter Comparison of the Safety and Efficacy of Gel Plus versus Restylane for the Correction of Nasolabial folds"
Coapt

August 2008

Assistant Director of Clinical Research, "A Multi-Center Concurrent Long Term Efficacy Data Collection Trial of GFX for Reduction of Glabellar Furrowing"
Advanced Cosmetic Intervention

August 2008

Assistant Director of Clinical Research, "A Prospective Double-Masked, Randomized, Open-Label, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Triple Therapy (IPL, Near-IR and Fractionated Er: YAG Laser 2940 nm wavelength) versus Single Therapy (IPL) for the Treatment of Moderate to Severe Photo Damage and Fitzpatrick Skin Types I – III"
Alma Laser

July, 2008

Clinical Coordinator, "Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A injections for Subjects with Mild to Moderate Acne Vulgaris"
Investigator Initiated, DeNova Research

July, 2008

Clinical Coordinator, "Altering First Impressions following Restylane"
Medicis Aesthetics

July, 2008

Clinical Coordinator, "Phase I Double-Blind, Randomized, Placebo Controlled Trial of Skin Health Experimental Product Verses Placebo taken twice daily to Support Healthy Skin"
Standard Process, Inc.

November, 2007

Program Coordinator,
"A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia"
AstraZeneca

August, 2007
Program Coordinator, "A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Patients with Depression Treatment Failure"
CNS Response, Inc.

June, 2007
Program Coordinator, "A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia"
Cephalon

December, 2006

Program Coordinator, "Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients"
Forest

November, 2006

Program Corrdinator, "An 8-week, randomized, double-blind, fixed-dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension"
Novartis

November, 2006

Program Coordinator, "Duloxetine Versus Placebo in the Long Term Treatment of Patients with Late-Life Major Depression"
Eli Lilly

September, 2006

Program Coordinator, "A Double-Blind, Placebo-Controlled Study of 6(S)-5-

MTHF among SSRI-Resistant Outpatients with Major Depressive Disorder"
PamLab

May, 2006

Program Coordinator, "A Placebo-controlled, Double-blind, Parallel-group, Dose Titration Study to Evaluate the Efficacy and Safety of Concerta® in Adults with Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg per day"
McNeil

May, 2006

Program Coordinator, "An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA® at Doses of 36 mg, 54 mg, 72 mg, 90 mg and 108 mg per day in Adults with Attention Deficit Hyperactivity Disorder"
McNeil

January, 2006

Program Coordinator, "Treatment-Resistant Depression Registry"
Cyberonics

January, 2006

Program Coordinator, "A Multi-Centre, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period"
AstraZeneca

September, 2005

Program Coordinator, "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling"
Somaxon

May, 2005

Program Coordinator, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XBD173 in Patients with Generalized Anxiety Disorder"
Novartis

January, 2005

Program Coordinator, "A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing

With Dapoxetine in the Treatment of Premature Ejaculation"
Johnson & Johnson

August, 2004

Program Coordinator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder"
Bristol-Myers Squibb

September, 2004

Program Coordinator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients with Bipolar I Disorder"
Bristol-Myers Squibb

May 2004

Program Coordinator, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients with Bipolar I Disorder with Major Depressive Episode"
Bristol-Myers Squibb

January 2004

Program Coordinator, "A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients"
AstraZeneca

February 2004

Program Coordinator, "A multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL™) and risperidone (RISPERDAL™) in the long-term treatment of patients with schizophrenia or schizoaffective disorder"
AstraZeneca

January 2004

Program Coordinator, "Quetiapine as an Adjunct to SSRIs in the Treatment of Depression"
AstraZeneca

October 2003

Program Coordinator, "Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients with Major Depression"
Eli Lilly

September 2003

Program Coordinator, " A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness"
Abbott

July 2003

Program Coordinator, "A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Dapoxetine HCl in the Treatment of Rapid Ejaculation" and "An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation"
Alza

March 2003

Program Coordinator, “Augmentation with Aripiprazole to Current Antidepressants in Depressed Patients Who Are Partial Responders”
Bristol-Myers Squibb

July 2002

Diagnostic Rater, "Prevention of Recurrence in Depression with Drugs and Cognitive Therapy"
NIMH

May 2002

Program Coordinator, "A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients with Major Depressive Disorder"
Pfizer

October 2001

Clinical Coordinator, “Paroxetine for the Prevention of Pegalated Interferon-Associated Depression in Patients with Chronic Hepatitis C”
Glaxo Smith Kline

October 2001

Clinical Coordinator, "A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension
Study of MK-0869 in the Treatment of Patients with Major Depressive Disorder with Melancholic Features"
Merck

October 2001

Clinical Coordinator, "Treatment of Major Depressive Disorder with Psychotic Features with Risperidone Monotherapy; Risperidone and Sertraline; or Haloperidol and Sertraline"
Janssen

August 2001

Clinical Coordinator, "Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without
Major Depressive Disorder"
Eli Lilly

December 2000

Clinical Coordinator, "An Acute and Continuation Phase Study of the Comparative Efficacy of Venlafaxine ER (Effexor XR) and Fluoxetine (Prozac) in Achieving and Sustaining Remission (Wellness) in Patients with Recurrent Unipolar Major Depression; Followed by a Long-Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially with Venlafaxine ER"
Wyeth

November 2000

Clinical Coordinator, "A Single Photon Emission Computed Tomography Study of the Effects of Vagal Nerve
Stimulation on Regional Cerebral Blood Flow in Patients with Treatment-Resistant Depression (An Appendix to Cyberonics Protocol D-02)"
Cyberonics, Inc.

September 2000

Clinical Coordinator, "A Phase 4, Multicenter, 6-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Safety and Efficacy of PROVIGIL (Modafinil) at Individually Titrated Doses of 100, 200, 300 or 400 mg/day as Adjunctive Therapy in Patients with Major Depressive Disorder Who Have Demonstrated a Partial Response to Antidepressant Therapy for a Current Major Depressive Episode"
Cephalon, Inc.

August 2000

Clinical Coordinator, "Systematic Treatment Enhancement Program for Bipolar Disorder"
NIMH/sponsor Massachusetts General Hospital

July 2000

Clinical Coordinator, "A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis System (NCP®) in Patients with Depression"
Cyberonics, Inc.

June 2000

Clinical Coordinator, "Comparison of the CNS Effects of Acute and Steady Doses of Sertraline in Healthy Volunteers"
MIICRO, Inc.

April 2000

Clinical Coordinator, "A Double-Blind, Parallel Comparison of Hypericum Extract LI 160 (St. John's Wort), Fluoxetine and Placebo in Major Depression"
Lichtwer Pharma AG

March 2000

Clinical Coordinator, "Open-Label Combination of Olanzapine and Fluoxetine in Major Depressive Disorder"

Eli Lilly

TRAINING CERTIFICATES

2019- present	Emsculpt
2018- present	HydraFacial
2016- present	Coolsculpting
2014- present	Liposonix
2014-present	Clear and Brilliant
2014- present	Thermage

April 2011- present	Cynosure (Laser Hair removal)
September 2010- present	Ulthera (ultherapy)
June 2010- present	Laser Hair Removal (Lumenis Duet)
January 2010- present	Pelleve Skin tightening
January 2010- present	Allergan Botox
January 2010- present	Allergan –Juvederm, Juvederm Ultra/Ultra Plus
June 2009-presnt	True University (acne tx and Techniques)
December 2009- present	Intraceuticals hyperbaric Oxygen Facial
August 2009- present	Bot-tox-A
August 2008- present	Alma Lasers

CERTIFICATIONS:

Jawline Definition Evaluation Scale (2018)

IGA and Lesion Count (2009)

Neuro cognitive evaluations (MATRICS) August, 2007

K-SADS-PL, August, 2006

Adult ADHD Investigator Symptom Rating Scale (AISRS) May, 2006

Vagus Nerve Stimulation- (VNS)- programmer Sept, 2005

Montgomery Asberg Depression Rating Scale- (MADRS) May, 2000

Hamilton Depression Rating Scale- (HAM-D) May, 2000

Young Mania Rating Scale- (YMRS) May, 2000

Positive and Negative Symptom Scale (PANSS) May, 2000

Positive and Negative Symptom Scale (PANSS) for children and adole. August, 2006

ORGANIZATIONS

Jan-2011- 2014	Board of Director's- Step Up Women's Network
1996-June, 2008	Rush-Presbyterian-St. Luke's Medical Center Chicago, IL *BLS Instructor *Documentation Committee Member *PNS Member

PROFESSIONAL SOCIETIES:

2016- present	American Academy of Dermatology Nurse Practitioners
2008- present	American Nursing Association
2008- present	Organization of Facial Plastic Surgery Assistants
2007-present	American Academy of Nurse Practitioners
2004 -2010	American Psychiatric Nursing Association